OUR MISSION
To conduct essential research on cannabinoids, establishing safety and efficacy, to create a pathway for FDA, EMA and MHRA compliant commercialisation.
To conduct essential research on cannabinoids, establishing safety and efficacy, to create a pathway for FDA, EMA and MHRA compliant commercialisation.
We hold an exclusive license from Green Space Labs Inc. for a unique line of cannabinoid-based substances. Our initial formulation has shown remarkable effectiveness in alleviating IBS symptoms in a real-world observational study of 225 patients. Our next step involves conducting a study compliant with EMA standards to assess its efficacy.
Our firm was set up as a joint venture of an American Green Space Labs Inc., Medi Ventures sp. z o.o., a Polish venture capital arm of Chicago Poland Ventures and a private individual from Poland.
On November 21st, 2024 CannabIBS obtained clearance to perform a Phase 2 clinical trial (EUCT 2024-514685-39-00) of GSL01-001 to test its impact on patients suffering from IBS with diarrhea.
Upon successful evaluation, we aim to conduct the Phase 3 study and consequently, to introduce this innovative formulation as an over-the-counter drug in the EU and UK markets.
For further details, please reach out via the contact form below.
At present, IBS remains incurable, impacting patients' quality of life with symptoms like abdominal pain, cramping, bloating, constipation, and diarrhea. Existing over-the-counter options offer limited or short-term relief, while prescribed medications are costly and have adverse effects, often targeting only one symptom. Our new drug aims to offer a much-needed solution, potentially benefiting 10% to 20% of the global population affected by this discomforting disease.
With one of our formulations, we intend to conduct crucial studies to secure EU drug registration, paving the way for phase 1 clinical trials on healthy volunteers.
We seek investors whose contribution would enable the successful kick-off of the studies.
Our network of collaborators includes five top labs across Poland and Slovakia. International team of experts from Poland, UK and USA ensures professional and ethical conduct aimed at obtaining the most reliable and valuable data for further phases 2 and 3 studies.
Cannabibs sp. z o. o.
ul. Marszałkowska 58 / 15
00-545 Warszawa
tel. +48 22 300 17 60
NIP: 7011132453
We launched our operations in Poland in March 2023 with significant funding support from the EU. The National Centre for Research and Development (NCBiR) in Poland, acting as the official link between the EU and beneficiaries, recognised our potential and provided seed capital in the amount of 752 000 PLN for our startup. Additionally, Medi Ventures, the Polish venture capital branch of Chicago Poland Ventures, contributed to our financial support.